NCT06344715 2024-04-03
Phase 1 Study Evaluating Safety and Tolerability of SL-T10, GX-I7, and Pembrolizumab Triple Combination in mCRPC.
SL VAXiGEN
Phase 1 Recruiting
Clinical Trials
1 trialsMetastatic Castration-resistant Prostate Cancer (mCRPC) × efineptakin alfa × Genitourinary × Clear all